Thought Leadership | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Blog | October 09, 2017

Venue Over An ANDA Defendant: D. Del. Weighs In

Blog | October 09, 2017

Mayo at Five: Are Traditional Method of Treatment Claims in Danger Under Section 101?

Blog | October 05, 2017

Legal Alert: Federal Circuit Faults PTO's Approach to Claim Amendments During IPR, But Allows PTO to Try to Fix the Problem

Blog | September 28, 2017

The Unclear Scope Of 'All Patent Rights' In Patent Exhaustion

Blog | September 20, 2017

A Review Of Willfulness Findings In Hatch-Waxman Actions

Blog | September 06, 2017

Mayo at Five: Eligibility of Diagnostic Method Claims

Blog | September 05, 2017

Inadequacy of PTAB's Procedures for Reviewing Late-Submitted Evidence Leads to Vacatur

Blog | August 03, 2017

Has Amgen Already Won Its BPCIA Dispute With Sandoz?

Blog | August 02, 2017

PTAB Splits on Instituting Challenges to Herceptin® Patents

Article | July 28, 2017

Practical Aftermath of 'TC Heartland': Book Your Flights for the Coasts

Blog | July 12, 2017

Pfizer Takes Aim at Herceptin® Patent at the PTAB

Blog | July 05, 2017

U.S. Trademark Office Clarifies Filing Deadlines for Resurrecting Dead Applications and Registrations